Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 vaccine candidates for new SARS-CoV-2 variants (Phase 2/3)
2024-000361-24Phase 2
- Sponsor
- BioNTech SE
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Primary endpoint: Primary Safety Substudies A, B and C.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-000361-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000361-24.